Matthew S. Bodenstein is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group where he advises clients in the fields of small molecule organic chemistry, pharmaceutical formulations, food science, polymer chemistry, material science, and related chemical technologies.
Matt regularly assists clients with creating and managing strategic patent portfolios, rendering freedom-to-operate and patentability opinions, managing complex and high priority patent prosecution (including “Track 1” applications), rendering validity and infringement opinions, and conducting and managing complex due diligence investigations in connection with acquisitions and licensing opportunities.
In addition to his focus on pure patent matters, Matt regularly helps clients draft and negotiate term sheets, license agreements, material transfer agreements, sponsored research agreements, confidentiality and nondisclosure agreements, and joint developments agreements.
Prior to joining Sterne Kessler, Matt was Intellectual Property Counsel at Medicis Pharmaceutical Corp. (now a division of Valeant Pharma). At Medicis, Matt managed patent prosecution, opinion, due diligence, and contract matters and worked closely with the company's project teams and Business Development group. Before joining Medicis, he was an associate and patent agent in the IP Group of an AmLaw 100 law firm.
Before becoming a lawyer, Matt spent two years in the CNS Medical Chemistry group at Pfizer, Inc. in its Groton, Connecticut research headquarters, where he synthesized neuronal nitric oxide synthase inhibitors. After his time at Pfizer, and following several years in graduate school, Matt worked in the Process Research and Development Group at Merck & Co., Inc., where he developed and optimized scalable synthetic procedures for the multi-kg production of clinical candidates.
Matt earned his J.D., cum laude, from Temple University Beasley School of Law, his M.S. in organic chemistry, and his B.S. in Chemistry, from the University of Pennsylvania.